- Home
- TXMD vs BCDA Comparison
TXMD vs BCDA Comparison
Compare TXMD & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- BCDA
- Stock Information
- Founded
- TXMD 2008
- BCDA N/A
- Country
- TXMD United States
- BCDA United States
- Employees
- TXMD N/A
- BCDA N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- TXMD Health Care
- BCDA Health Care
- Exchange
- TXMD Nasdaq
- BCDA Nasdaq
- Market Cap
- TXMD 12.7M
- BCDA 11.3M
- IPO Year
- TXMD N/A
- BCDA N/A
- Fundamental
- Price
- TXMD $1.06
- BCDA $1.54
- Analyst Decision
- TXMD
- BCDA Strong Buy
- Analyst Count
- TXMD 0
- BCDA 1
- Target Price
- TXMD N/A
- BCDA $25.00
- AVG Volume (30 Days)
- TXMD 17.5K
- BCDA 94.6K
- Earning Date
- TXMD 11-11-2025
- BCDA 11-12-2025
- Dividend Yield
- TXMD N/A
- BCDA N/A
- EPS Growth
- TXMD N/A
- BCDA N/A
- EPS
- TXMD N/A
- BCDA N/A
- Revenue
- TXMD $2,559,000.00
- BCDA N/A
- Revenue This Year
- TXMD $427.09
- BCDA N/A
- Revenue Next Year
- TXMD N/A
- BCDA N/A
- P/E Ratio
- TXMD N/A
- BCDA N/A
- Revenue Growth
- TXMD 156.93
- BCDA N/A
- 52 Week Low
- TXMD $0.70
- BCDA $1.54
- 52 Week High
- TXMD $2.44
- BCDA $3.25
- Technical
- Relative Strength Index (RSI)
- TXMD 40.43
- BCDA 29.50
- Support Level
- TXMD $1.06
- BCDA $2.11
- Resistance Level
- TXMD $1.14
- BCDA $2.29
- Average True Range (ATR)
- TXMD 0.05
- BCDA 0.12
- MACD
- TXMD -0.00
- BCDA -0.04
- Stochastic Oscillator
- TXMD 5.26
- BCDA 0.66
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).